Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemaura’s glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center; he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as a world-renowned thought leader in obesity management in diabetes, medical nutrition and digital health, and has impacted the space through many discoveries and innovations. He provides expertise in understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss with current research in the cardiovascular benefits of short- and long-term weight reduction in obese individuals with and without type 2 diabetes. “We are truly gratified to have a practicing clinician that has changed the real-world treatment of diabetes management as an advisor to us for some upcoming KOL studies,” said Nemaura CEO Dr. Faz Chowdhury in the press release. “These studies will allow us to better impact patient health, and we expect the counsel and input from Dr. Hamdy to be meaningful in helping us to deliver non-invasive treatment options to further enrich people’s lives.”
To view the full press release, visit https://ibn.fm/avf6X
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php